Immunotherapy company Biopharmaceutical New Technologies or BioNTech SE announced Wednesday a profit for the fourth quarter compared to a loss last year, driven by the continued global delivery of its COVID-19 vaccine. The company also reiterated its COVID-19 vaccine revenue guidance for the full-year 2022.
from RTT - Top Story https://ift.tt/dOmzLyX
via IFTTT
from RTT - Top Story https://ift.tt/dOmzLyX
via IFTTT
Comments
Post a Comment